文献速递MDS 与骨髓增殖性肿瘤

用于成人骨髓增生异常综合征预后判断的4-lncRNA评分系统

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2017-08-16

该研究在176例成人原发性骨髓增生异常综合征(MDS)患者中分析长链非编码RNA(lncRNA)表达,识别出4个与总生存(OS)显著相关的lncRNA并构建加权风险评分系统。较高lncRNA评分与更高骨髓原始细胞比例、更高危MDS亚型、复杂核型及RUNX1、ASXL1、TP53、SRSF2、ZRSR2突变相关,与SF3B1突变负相关;高评分患者OS显著更短、5年白血病转化率更高,且在多变量分析中为OS的独立不良危险因素(相对危险度4.783;P < .001)。

要点

  • 4-lncRNA风险评分与MDS患者总生存显著相关,高评分者OS更短。
  • 高lncRNA评分与更高骨髓原始细胞比例、更高危亚型及复杂核型相关。
  • 多变量分析中高lncRNA评分为OS独立不良危险因素(相对危险度4.783;P < .001)。

核心结论

  • 整合的4-lncRNA风险评分系统与MDS患者独特的临床和生物学特征相关,并作为生存和白血病转化的独立预后因素。
  • 该基于lncRNA的评分系统有潜力改善当前MDS患者的风险分层。

研究设计与样本

  • 在176例成人原发性MDS患者中分析lncRNA表达谱,识别与总生存显著相关的4个lncRNA。
  • 以4个lncRNA表达的加权和构建风险评分系统,并在独立MDS队列中验证其预后意义。

主要发现

  • 较高lncRNA评分与更高骨髓原始细胞比例、基于IPSS-R和世界卫生组织分类的更高危MDS亚型、复杂细胞遗传学改变相关。
  • 较高lncRNA评分与RUNX1、ASXL1、TP53、SRSF2和ZRSR2突变相关,与SF3B1突变呈负相关。
  • 较高lncRNA评分患者较低评分患者总生存显著更短、5年白血病转化率更高。
  • 多变量分析中,较高lncRNA评分在校正年龄、细胞遗传学、IPSS-R和基因突变后仍为OS的独立不良危险因素(相对危险度4.783;P < .001)。

关键数值与推荐

  • 4-lncRNA风险评分以4个lncRNA表达的加权和计算。
  • 多变量分析中较高lncRNA评分对OS的相对危险度为4.783(P < .001)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long noncoding RNAs (lncRNAs) not only participate in normal hematopoiesis but also contribute to the pathogenesis of acute leukemia. However, their clinical and prognostic relevance in myelodysplastic syndromes (MDSs) remains unclear to date. In this study, we profiled lncRNA expressions in 176 adult patients with primary MDS, and identified 4 lncRNAs whose expression levels were significantly associated with overall survival (OS). We then constructed a risk-scoring system with the weighted sum of these 4 lncRNAs. Higher lncRNA scores were associated with higher marrow blast percentages, higher-risk subtypes of MDSs (based on both the Revised International Prognostic Scoring System [IPSS-R] and World Health Organization classification), complex cytogenetic changes, and mutations in RUNX1, ASXL1, TP53, SRSF2, and ZRSR2, whereas they were inversely correlated with SF3B1 mutation. Patients with higher lncRNA scores had a significantly shorter OS and a higher 5-year leukemic transformation rate compared with those with lower scores. The prognostic significance of our 4-lncRNA risk score could be validated in an independent MDS cohort. In multivariate analysis, higher lncRNA scores remained an independent unfavorable risk factor for OS (relative risk, 4.783; P < .001) irrespective of age, cytogenetics, IPSS-R, and gene mutations. To our knowledge, this is the first report to provide a lncRNA platform for risk stratification of MDS patients. In conclusion, our integrated 4-lncRNA risk-scoring system is correlated with distinctive clinical and biological features in MDS patients, and serves as an independent prognostic factor for survival and leukemic transformation. This concise yet powerful lncRNA-based scoring system holds the potential to improve the current risk stratification of MDS patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yao CY, Chen CH, Huang HH, et al. A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes. Blood Adv. 2017. PMID: 29296792. doi:10.1182/bloodadvances.2017008284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。